• Develop and implement effective sales strategy, BD plans and exceed objectives established in the strategic planning. •GTM strategy of new AI Bioinformatic service platform as a CRO/CDMO offering, SaaS with Marketing and R&D, leading marketing campaigns of new products. • Develop robust forecast models ensuring seamless integration of market and customer insights into accurate forecasts that contribute to corporate investment to inform company strategy. • Corporate development duties with significant experience conducting qualitative and quantitative market research and competitive intelligence, to effectively direct corporate strategy. • Quarterly financial forecasting directly answerable to CEO and VP of Global Sales. • Salesforce and Tableau expert, training and companywide development. Actively provide coaching and mentoring to team members

• Managing university and government institutions across UK/IE territory. • Quarterly financial forecasting directly answerable to CEO and VP of Global Sales• B2B and B2C clients, range of markets from Academia, Clinical Trials and Hospitals.• Contracting, negotiations, pipeline development, company mapping and marketing development.• Promotion to Regional Business Director

• Process Development Consultant and Business Development Executive focused on Cell and Gene Therapies, CAR-T, DNA,• Vaccines and traditional biopharma production.• Development of whole process pipeline fed-batch/perfusion process platforms for multiple cell typesin controlled bioreactors with a variety of systems including 2000L to bench- top reactors and highthroughput technologies such as Ambr15, Ambr250, Streamlink CC, with SIMCA.• Managing major clients for bioprocessing/biopharma in the UK, in close collaboration with development consultants and specialists for the territory.• Transforming yearly sales with exponential return through a reinvigorated network within the biopharma space based on trust and expert knowledge.• Financial forecasting with extensive Salesforce and Tableau work (building reports and data sets).

• Research and product development on DNA nanotechnology embedded in microfluidics to develop the next generation of rapid early stage diagnostics (genetics and proteomics)• Leading research and commercial functions, successful in raising PE financing and public grants and building a team of scientists for product development.• Combing DNA nanotechnology with the high sensitivity of DNA aptamers to provide ultra sensitive readouts that provide rapid evaluation of a range of diseases/infections. • Development of novel multi-omic platform for a range Neurodegenerative and Infectious diseases.• Patented technology, ARSEANL (Aptamer-Release-Strand-Enhance-Amplification of Nucleicacids-in Liquids). Utilising enzymatic amplification to achieve ultra-low sensitivity (fM) throughstrategic DNA nanostructures encompassing DNA aptamer detection of proteins and metabolites and genetic readouts.Involving product development and prototype construction of a portable laser based readout for point of care diagnostics.

Lecturer in Biochemical Engineering and Lecturer in Organic ChemistryModules taught: introduction into DNA, biopharma drugdevelopment, Mammalian/Microbial fermentation and purification for DNA/protein/cell and gene therapies; DNA sequencing and DNA based diagnostics.

• Research and development of DNA nanopores to generate novel bio-sensing devices.• DNA nanopores for targeted drug delivery and bio-therapeutic applications, through thermalsensitivity and protein gated applications. Including membrane physics and insertion studies.• Patented technology launched for small molecule drug delivery systems, taken to phase II clinicaltrials with use after successful trials in mice and organoid models.• Additional work has focused on the development of analytical techniques to measure the interaction between DNA nanopores and lipid bilayers.

• Yearly financial planning and price negotiations.• Management and building high performance teams UK and EU• Year on year growth of global business from, through consulting, CRO work, investments and start-up venture development. B2B sales and contract negotiations with C-Suite executives. • Quarterly forecasting, responsible for all EU business and global marketing.• Transformed lead generation, implementation of targeted marketing, >600% increase in outreach.• Pivotal role in setting up organisational structure, future strategy, vision and mission of IF at the local and global levels. • Build, develop and maintain partnership and collaboration with the customers: investors, venture capitalists and key opinion leaders in business and pharmaceutical industry.• Multiple global partnerships (US), memberships (UK, Europe) and media partnership agreements (Europe, UK) • Maintain up-to-date CRM and monitor accuracy and completeness of data in designated regions.• Development of BD/Sales training programs for the regional BD teams

• Hunting early-stage business ventures to generate sales with programmes and consulting services.• Building networks and diversity between academia, biotechnology companies and investors.• Leading pitches to new business partners and presenting at conferences.

Research Placement Somers Cancer Research Centre, University of Southampton, Cancer Research UK.Research into anti-apoptotic pathways within breast cancer. Development of a Reverse Two Hybrid System (RTHS) and chromosomal integration for detection of protein interactions. Screening with SICLOPPS technology. Vector construction PcDNA3 for expression in MCF7 breast cancer cell line and pTHCP-14 vector for RTHS.

Research project into organic multi-porphyrin DNA nano-wire.Solid phase DNA synthesis with modified nucleotides, analysed by CD-spectroscopy. Synthesis of an array of modified nucleotides via organometallic catalysed reactions.

Collaborative Research Project at Optoelectronics Research Centre.Development of a: Novel Optical-Diagnostic Technology for Lymphnode Analysis. Laser based direct cell PCR and cell lysis. Development of a prototype suitable for use in surgical theatre